Biomedical · us
New Pancreatic Cancer Drug Daraxonrasib Pushes the Survival Curve Forward, and Pushes Approval Pressure to the FDA’s Doorstep
A once-daily oral drug has widened the gap with chemotherapy in an advanced pancreatic cancer trial; the real new question has shifted from whether KRAS can be targeted to which patients can receive it early and how long the benefit can last.
Pancreatic cancer weighs heavily on clinicians and patients not only because it is often found only at an advanced stage, but also because available drugs have long rarely been able to clearly rewrite the course of the disease. The survival gap shown by daraxonrasib in a metastatic pancreatic cancer trial is therefore not just another set of new drug data, but a sign that a cancer-driving pathway once considered difficult to drug has been pushed to the edge of real-world treatment options.
According to AP and multiple reports from the same venue, Revolution Medicines’ oral RAS inhibitor daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in previously treated patients with advanced pancreatic cancer. The Guardian reported that the data were presented at the annual meeting of the American Society of Clinical Oncology in Chicago, with about 500 patients participating; median survival was 13.2 months in the daraxonrasib group and about 6.6 to 6.7 months in the chemotherapy group.
Le Monde described the trial details somewhat differently, saying the final international trial included 460 patients with an average age of 65.5 years, enrolled between October 2024 and November 2025, and randomly assigned to receive oral daraxonrasib or conventional chemotherapy; its report calculated median survival at about 13 months and 6 days, versus about 6 months and 21 days in the control group. Different media outlets vary somewhat in sample size and wording, but the core signal is consistent: in metastatic pancreatic cancer, a disease with an extremely poor prognosis, the survival curves separated by an uncommon margin.
The scientific focus of this drug is RAS/KRAS signaling. KRAS mutations are common drivers in multiple cancers and are especially critical in pancreatic ductal adenocarcinoma; daraxonrasib is described as a RAS(ON) multi-selective inhibitor, intended to suppress RAS signaling in its activated state rather than target only a single mutation subtype. If this strategy holds up in a broader patient population, its significance would go beyond a single drug itself, because it touches the root problem of pancreatic cancer’s long-standing lack of effective targeted therapies.
Safety will also affect approval and clinical use. Le Monde reported that the proportion of patients who discontinued treatment because of side effects was about 3% in the daraxonrasib group and about 6% in the chemotherapy group; however, daraxonrasib is not without costs, with serious or clinically significant rash affecting about 14% of patients. This means an oral drug is not the same as an easy treatment, and if it moves into routine use, skin toxicity, dose adjustment, and real-world tolerability will all need to be managed clearly.
The regulatory timetable is also accelerating. The U.S. Food and Drug Administration said it had allowed Revolution Medicines to initiate an expanded access treatment program for daraxonrasib, applicable to previously treated patients with metastatic pancreatic ductal adenocarcinoma; the FDA also said the application was received on April 28, 2026, and that a may-proceed letter was issued on April 30. The drug had previously received breakthrough therapy and orphan drug designations, as well as a Commissioner’s National Priority Voucher, showing that regulators are willing to advance review and accessibility in parallel.
Still, this is not an announcement of a cure. The available information mainly comes from conference presentations and media reports, and the full paper, subgroup analyses, quality-of-life data, the impact of subsequent treatments, and resistance mechanisms will still determine its real place in clinical practice. For patients, median survival of around 13 months is not an endpoint, but it may be a substantive advance rarely seen in years; for the research and development field, daraxonrasib’s test has only just begun, because making a difficult-to-treat cancer retreat briefly and keeping it under long-term control are two different things.